Eculizumab as a fast-acting rescue therapy in a refractory myasthenic crisis: a case report

J Neurol. 2022 Nov;269(11):6152-6154. doi: 10.1007/s00415-022-11222-8. Epub 2022 Jun 16.

Authors

Camilla M M Strano^#^{1

2}, Benedetta Sorrenti^#^{1

2}, Luca Bosco^{1

2}, Yuri M Falzone¹, Raffaella Fazio¹, Massimo Filippi^{3

4

5

6

7}

Affiliations

¹ Neurology Unit, IRCCS San Raffaele Scientific Institute, Via Olgettina, 60, 20132, Milan, Italy.
² Vita-Salute San Raffaele University, Milan, Italy.
³ Neurology Unit, IRCCS San Raffaele Scientific Institute, Via Olgettina, 60, 20132, Milan, Italy. [email protected].
⁴ Vita-Salute San Raffaele University, Milan, Italy. [email protected].
⁵ Neuroimaging Research Unit, Division of Neuroscience, Institute of Experimental Neurology, IRCCS San Raffaele Scientific Institute, Milan, Italy. [email protected].
⁶ Neurophysiology, IRCCS Unit San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy. [email protected].
⁷ Neurorehabilitation Unit, San Raffaele Scientific Institute, Milan, Italy. [email protected].

^# Contributed equally.

PMID: 35705882
DOI: 10.1007/s00415-022-11222-8

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Humans
Myasthenia Gravis* / complications
Myasthenia Gravis* / drug therapy
Thymectomy

Substances

Antibodies, Monoclonal, Humanized
eculizumab